Business News

2023 Biopharmaceutical Industry Intellectual Property Xianghu Forum and China Biopharmaceutical Patent Competition Award Ceremony（referred to as "Xianghu Forum）YúNovember 24th-It will be held at Hangzhou Water Park Hotel on the 25th.

China (Xiaoshan) High-Value Patent Cultivation Competition for Biopharmaceutical Industry(Also known as “China Biopharmaceutical Patents Competition”)It is the first high-value patent cultivation competition for a specific industry in the country, as well as the first intellectual property event focused on the biomedical industry nationwide. A total of 209 outstanding projects from 23 provinces, cities, and autonomous regions across the country, along with those overseas, have registered to participate, mainly in areas such as pharmaceuticals, high-end medical devices, and health care.。

After the preliminary and semi-final selections,Total16 innovative projects with high innovation levels, strong market competitiveness, and advantages in patent development and layout advanced to the final round.

InNovemberDay 24OrganizeIn the final competition, Haisco Medicine Group’s project “Long-acting hypoglycemic Class I new drug HSK7653” demonstrated its innovative advantages through project presentations, roadshows, expert questions, and summary speeches. It also shared practical experiences in cultivating high-value patents, and won the second prize in the competition.

11On the 25th of the month, Yan Pangke, director and deputy general manager of Hisco Pharmaceutical GroupMr.Invited to attend the 2023 Biopharmaceutical Industry Intellectual Property Xianghu Forum and the China Biopharmaceutical Patent Competition Award Ceremony, and delivered a speech at the main forum.PROTACKeynote speech on "Protein Degradation Technology".

    This competition has established a platform for the cultivation, exchange, and value realization of high-quality patents in the biopharmaceutical industry. Haisco Medicine Group will continue to focus on high-quality innovation and research concepts, and carry out more comprehensive and valuable patent strategies, thereby contributing to the high-level development of biopharmaceutical companies.